ORIC-101 (1-1000 nM) dose-dependently decreases the expression of n GR-mediated target gene (IC50s: 17.2 and 21.2 nM, respectively). ORIC-101 displays markedly reduced androgen receptor agonism (EC50, 2500 nM) and CYP2C8 and CYP2C9 inhibition profiles (IC50, >10 μM)[1].

In OVCAR5 xenograft tumor in cortisol-treated mice, ORIC-101 (75 mg/kg, P.O. twice a day for 16-22 days) increases the anti-tumor activity in combination with gemcitabine and carboplatin[1].